Renal Hemophilic Pseudotumors
Back to listReview Article
Renal Hemophilic Pseudotumors
Emel Gürkan
Affiliation: Department of Haematology, C¸ ukurova University Medical School, Adana, Turkey
Submission date: 1st July 2009, Revision date: 2nd August 2009, Acceptance date: 10th August 2009
ABSTRACT
Severe hemophilic patients are prone to develop long‐term sequelae such as pseudotumor formation caused by repeated and unresolved hematomas leading to subsequent encapsulated mass lesion. Among these, renal hemophilic pseudotumors are seen as a rather rare event. Once developed, this serious condition should be approached carefully, first by maintaining adequate hemostasis with appropriate factor replacement therapy and, later on, complete surgical excision should be targeted. Without surgical intervention, complete resolution is generally not possible. Other treatment modalities such as radiotherapy may be helpful in addition to surgery preoperatively in order to reduce bleeding complications. However, experience of this approach is limited to those pseudotumors of other sites such as bone and pelvic pseudotumors. Rarely, a true pseudotumor may mimic a malignancy; therefore, accurate assessment by radiological means is required. Considering the difficulties in management, it is of great importance to constitute early substitutive treatment for the prevention of pseudotumors.
Keywords: renal pseudotumor, hemophilia, management
Correspondence: Emel Gürkan, Çukurova University Faculty of Medicine, Department of Hematology, 01330 Adana, Turkey
Other Articles
- Prophylaxis with Once, Twice or Three-Times Weekly Dosing of rFVIII-FS prevents Joint Bleeds in a Previously Treated Pediatric Population with Moderate/Severe Hemophilia A
- Current Practice in Clinical Thrombosis and Hemostasis
- Review of the Literature of FEIBA Administration in Patients with Hemophilia B and Inhibitors
- Decreased Bone Mineral Density in Adult Patients with Hemophilia: Clinical Significance, Prevalence and Risk Factors
- Safety of Recombinant Factor VIII Therapy: Focus on Inhibitor Development
